On the other hand, while benefits in overall survival are observed in all patients, it remains uncertain whether the triplet therapy-combining androgen receptor signaling inhibitors, androgen deprivation therapy, and docetaxel should be the standard of care for all patients with metastatic castration-sensitive prostate cancer (mCSPC) [26]. This evidence concerns the gene AR and prostate cancer.